1
|
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. J Clin Med 2022; 11:jcm11061511. [PMID: 35329838 PMCID: PMC8950226 DOI: 10.3390/jcm11061511] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/08/2022] [Accepted: 03/08/2022] [Indexed: 02/04/2023] Open
Abstract
Background: The most frequent inflammatory skin diseases are psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne. Their management is challenging for dermatologists since their relapsing chronic clinical course is associated with a great impact on quality of life. Nevertheless, the recent introduction of novel therapies, such as biological drugs and small molecules has been changing the history of these diseases. Methods: A systematic review of the scientific literature of case reports, case series, epidemiological studies, reviews, and systematic reviews regarding teledermatology and inflammatory skin disease. Studies were identified, screened, and extracted for relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: A total of 69 cases articles were included in the review. Conclusions: As we have shown in the review, several experiences of teledermatology for patients affected by inflammatory skin diseases have been demonstrated to increase due to clinical access to hospital and specialized health care services, allowing better access to specialized dermatology care for people living in remote areas, and saving costs and money with health care.
Collapse
|
2
|
Havelin A, Hampton P. Telemedicine and e-Health in the Management of Psoriasis: Improving Patient Outcomes – A Narrative Review. Psoriasis (Auckl) 2022; 12:15-24. [PMID: 35320971 PMCID: PMC8935082 DOI: 10.2147/ptt.s323471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 02/15/2022] [Indexed: 12/13/2022] Open
Abstract
The role of technology in dermatology is expanding. Telemedicine and eHealth are increasingly being used by doctors and patients in the management of psoriasis. This is a narrative review of the literature relating to the use of digital technology in the management of psoriasis. We divided psoriasis e-health into three areas: mobile phone applications, teledermatology and artificial Intelligence (AI). Literature searches were conducted using the following databases: Pubmed, Google Scholar, Scopus, both app stores using App Annie platform. The following words were used in searches; psoriasis, dermatology, mobile phone application, application, app, smartphone, teledermatology, telemedicine, artificial intelligence, AI, machine learning in various combinations. We defined three key questions, one relating to each of the 3 areas. We then reviewed the relevant papers found in the searches and selected the papers of highest research quality and greatest relevance in order to answer the questions. In addition, for apps, operating systems for IOS and android devices were searched for apps containing the key word “psoriasis” in the title using the app analytic website www.appannie.com on 08/11/21. Research publications linked to these apps were reviewed.
Collapse
Affiliation(s)
- Alison Havelin
- Department of Dermatology, Newcastle Hospitals NHS Trust, Newcastle, UK
| | - Philip Hampton
- Department of Dermatology, Newcastle Hospitals NHS Trust, Newcastle, UK
- Correspondence: Philip Hampton, Email
| |
Collapse
|
3
|
Svendsen MT, Tiedemann SN, Andersen KE. Pros and cons of eHealth: A systematic review of the literature and observations in Denmark. SAGE Open Med 2021; 9:20503121211016179. [PMID: 34046178 PMCID: PMC8135209 DOI: 10.1177/20503121211016179] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 04/16/2021] [Indexed: 01/04/2023] Open
Abstract
Objectives: The main objectives of this article are to systematically review the recent literature on patient safety in relation to the use of eHealth and to investigate how the Danish authorities supervise private eHealth clinics with regard to patient safety. Methods: Original studies reporting the association between patient safety and the use of eHealth as a means of communication between patients and healthcare providers were included. Four literature databases were searched for English-language articles reporting results from cohort studies and clinical trials, published from 2015 until March 2021. Moreover, registered private eHealth clinics in Denmark were evaluated with reference to a recent national audit of patient safety issues in eHealth. Results: The literature search retrieved four intervention studies. The studies did not identify any particular patient safety risks associated with the use of eHealth. Many different authorized healthcare providers (preferably, doctors) apply eHealth in various contexts. eHealth is being used as the only form of contact between the healthcare provider and the patient, as a supplement to patient visitations in an outpatient clinic, or as a tool for communicating between two or more healthcare providers. The regulation of eHealth involves patient safety issues but also has interfaces to marketing, IT systems, and infrastructure. Supervision of eHealth includes the organization of clinics, handling patient charts, prescription medicine, patient legal rights, and patient transition. However, there are many interfaces in the division of responsibilities among the various governmental players. Conclusion: eHealth is being used increasingly and in many settings, although recently published intervention studies investigating patient safety issues by the use of eHealth are limited. A structured and continuous governmental control and regulation of patient safety in relation to the use of eHealth is warranted.
Collapse
Affiliation(s)
- Mathias T Svendsen
- Department of Clinical Research, University of Southern Denmark, Odense M, Denmark
| | - Sylvia N Tiedemann
- Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Klaus Ejner Andersen
- Department of Clinical Research, University of Southern Denmark, Odense M, Denmark
| |
Collapse
|
4
|
Svendsen MT, Andersen F, Andersen KH, Pottegård A, Johannessen H, Möller S, August B, Feldman SR, Andersen KE. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol 2018; 179:1062-1071. [PMID: 29654699 DOI: 10.1111/bjd.16667] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2018] [Indexed: 01/10/2023]
Abstract
BACKGROUND Adherence to topical psoriasis treatments is low, which leads to unsatisfactory treatment results. Smartphone applications (apps) for patient support exist but their potential to improve adherence has not been systematically evaluated. OBJECTIVES To evaluate whether a study-specific app improves adherence and reduces psoriasis symptoms compared with standard treatment. METHODS We conducted a randomized controlled trial (RCT, clinicaltrials.gov registration: NCT02858713). Patients received once-daily medication [calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam] and were randomized to no app (n = 66) or app intervention (n = 68) groups. In total, 122 patients (91%) completed the 22-week follow-up. The primary outcome was adherence, which was defined as medication applied ≥ 80% of days during the treatment period and assessed by a chip integrated into the medication dispenser. Secondary outcomes were psoriasis severity measured by the Lattice System Physician's Global Assessment (LS-PGA) and quality of life, measured using the Dermatology Life Quality Index (DLQI) at all visits. RESULTS Intention-to-treat analyses using regression was performed. More patients in the intervention group were adherent to Cal/BD cutaneous foam than those in the nonintervention group at week 4 (65% vs. 38%, P = 0·004). The intervention group showed a greater LS-PGA reduction than the nonintervention group at week 4 (mean 1·86 vs. 1·46, P = 0·047). A similar effect was seen at weeks 8 and 26, although it did not reach statistical significance. CONCLUSIONS This RCT demonstrates that the app improved short-term adherence to Cal/BD cutaneous foam treatment and psoriasis severity.
Collapse
Affiliation(s)
- M T Svendsen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.,Centre for Innovative Medical Technology (CIMT), Clinical Institute, University of Southern Denmark, Odense, Denmark.,Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.,Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - F Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.,Dermatological Investigations Scandinavia, University of Southern Denmark, Odense, Denmark
| | - K H Andersen
- Dermatological Investigations Scandinavia, University of Southern Denmark, Odense, Denmark
| | - A Pottegård
- Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.,Hospital Pharmacy, Odense University Hospital, Odense, Denmark
| | - H Johannessen
- Research Unit of User Perspectives, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - S Möller
- Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark.,Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | | | - S R Feldman
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.,Department of Dermatology (Center for Dermatology Research), Wake Forest School of Medicine, Winston-Salem, NC, U.S.A
| | - K E Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.,Centre for Innovative Medical Technology (CIMT), Clinical Institute, University of Southern Denmark, Odense, Denmark.,Dermatological Investigations Scandinavia, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
5
|
Svendsen MT, Andersen F, Andersen KH, Andersen KE. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial. BMC DERMATOLOGY 2018; 18:2. [PMID: 29415699 PMCID: PMC5804085 DOI: 10.1186/s12895-018-0071-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Accepted: 01/30/2018] [Indexed: 01/22/2023]
Abstract
Background Topical corticosteroid or corticosteroid/calcipotriol preparations are recommended first-line topical treatments of psoriasis, but a main cause for the lack of efficacy of topical treatments is considered low rates of adherence to topical drugs. Patient support by the use of applications (apps) for smartphones is suggested to improve medical adherence. Methods/design Design: An investigator-initiated, single-center, single-blind, parallel-group, phase-4 clinical superiority randomized controlled trial (RCT). Participants: 134 patients 18 to 75 years of age with mild-to-moderate psoriasis, who are capable of reading English language, own a smartphone, and are candidates for the study drug calcipotriol and betamethasone dipropionate (Cal/BD) cutaneous foam once daily prn (pro re nata). Intervention: A 28-day adherence-supporting app providing compulsory daily treatment reminders that pop-up on the smartphone screen with a short alert sound. The app synchronizes through Bluetooth® to an electronic monitor (EM) attached to the medication canister. The EM contains a chip registering the amount of foam, day and time the patient use the foam dispenser. The information is displayed in a diary that shows the amount of Cal/BD cutaneous foam used and the number of applied treatment sessions. The app has an optional diary with the patient’s rating of symptoms. Non-intervention: Use of Cal/BD cutaneous foam and EM without the app. All participants are prescribed Cal/BD cutaneous foam prn for the entire study period. Primary outcome obtained in week 4: rates of adherence measured by patient report, weight of medication canisters, and number of treatment sessions measured by the EM. Secondary outcomes obtained at baseline, weeks 4, 8, and 26: Lattice System Physician’s Global Assessment (LS-PGA) and Dermatology Quality of Life Index (DLQI). Discussion This trial tests of whether an app can improve rates of adherence to a topical antipsoriatic drug. If the app improves rates of adherence and reduces the burden of psoriasis in a clinically significant way, the app could easily be implemented as a standard routine of care in the clinic. Trial registration NCT02858713, registered on August 3, 2016. EudraCT number 2016–002143-42. Electronic supplementary material The online version of this article (10.1186/s12895-018-0071-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Mathias Tiedemann Svendsen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Kløvervænget 15, 5000, Odense C, Denmark. .,Centre for Innovative Medical Technology, Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark. .,Odense Patient data Explorative Network (OPEN), Odense University Hospital, Odense, Denmark. .,Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
| | - Flemming Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Kløvervænget 15, 5000, Odense C, Denmark.,Dermatological Investigations Scandinavia (DIS), University of Southern Denmark, Odense C, Denmark
| | - Kirsten Hammond Andersen
- Dermatological Investigations Scandinavia (DIS), University of Southern Denmark, Odense C, Denmark
| | - Klaus Ejner Andersen
- Department of Dermatology and Allergy Centre, Odense University Hospital, Kløvervænget 15, 5000, Odense C, Denmark.,Centre for Innovative Medical Technology, Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark.,Dermatological Investigations Scandinavia (DIS), University of Southern Denmark, Odense C, Denmark
| |
Collapse
|